Equities
Health CarePharmaceuticals and Biotechnology
  • Price (USD)10.87
  • Today's Change0.04 / 0.37%
  • Shares traded298.02k
  • 1 Year change-23.13%
  • Beta1.5334
Data delayed at least 15 minutes, as of Sep 20 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 19-Sep-24
Select bar for recommendation details.
Recommendations19-Sep-24
Buy1
Outperform4
Hold3
Sell0
Strong Sell0

Share price forecast in USD

The 5 analysts offering 12 month price targets for AVITA Medical Inc have a median target of 15.00, with a high estimate of 21.00 and a low estimate of 9.00. The median estimate represents a 37.99% increase from the last price of 10.87.
High93.2%21.00
Med38.0%15.00
Low-17.2%9.00

Earnings history & estimates in USD

On Aug 08, 2024, AVITA Medical Inc reported 2nd quarter 2024 losses of -0.600 per share.
The next earnings announcement is expected on Nov 07, 2024.
Average growth rate-27.05%
AVITA Medical Inc reported annual 2023 losses of -1.40 per share on Feb 22, 2024.
Average growth rate+7.06%
More ▼

Revenue history & estimates in USD

AVITA Therapeutics, Inc. had 2nd quarter 2024 revenues of 15.20m. This bettered the 14.73m consensus of the 6 analysts covering the company. This was 44.03% above the prior year's 2nd quarter results.
Average growth rate+8.80%
AVITA Therapeutics, Inc. had revenues for the full year 2023 of 50.14m. This was 45.68% above the prior year's results.
Average growth rate+56.13%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.